Clinical Trial Detail

NCT ID NCT03955783
Title Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Michael Byrne
Indications

diffuse large B-cell lymphoma

acute myeloid leukemia

Therapies

Selinexor + Venetoclax

Age Groups: adult senior

No variant requirements are available.